Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis

Thoracic Cancer

Volumn 6, Issue 3, 2015, Pages 288-295

  Ma, Yunfan ^a   Fan, Mengying ^a   Dai, Liang ^a   Kang, Xiaozheng ^a   Liu, Yiqiang ^a   Sun, Yu ^a   Xiong, Hongchao ^a   Liang, Zhen ^a   Yan, Wanpu ^a   Chen, Keneng ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Immunohistochemistry; Lung squamous cell carcinoma; Non small cell lung cancer; Prognosis

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; PROTEIN P40; PROTEIN P63;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL LUNG CARCINOMA; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

EID: 84928258611     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12181     Document Type: Article

References (25)

1. Linardou H, Dahabreh IJ, Kanaloupiti D etal. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
2. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817-1824.
3. Soda M, Choi YL, Enomoto M etal. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
4. Pelosi G, Sonzogni A, Viale G. The classification of lung carcinoma: time to change the morphology-based approach? Int J Surg Pathol 2010; 18: 161-172.
5. Travis WD, Brambilla E, Noguchi M etal. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
6. Solis LM, Behrens C, Dong W etal. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010; 16: 3743-3753.
7. Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol 2004; 35: 3-7.
8. Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 2010; 5: 349-371.
9. Nobre AR, Albergaria A, Schmitt F. p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63. Acta Cytol 2013; 57: 1-8.
10. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35: 15-25.
11. Whithaus K, Fukuoka J, Prihoda TJ, Jagirdar J. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med 2012; 136: 155-162.
12. Kwak EL, Bang YJ, Camidge DR. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
13. Yoshida A, Tsuta K, Watanabe S. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011; 72: 309-315.
14. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012; 25: 405-415.
15. Nonaka D. A study of DeltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 2012; 36: 895-899.
16. Sundström BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Int J Biol Markers 1994; 9: 102-108.
17. Cooper D, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations. Lab Invest 1985; 52: 243-256.
18. Miettinen M. Keratin immunohistochemistry: update of applications and pitfalls. Pathol Annu 1993; 28 (Pt 2): 113-143.
19. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001; 116: 823-830.
20. Carella R, Deleonardi G, D'Errico A etal. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001; 25: 43-50.
21. Downey P, Cummins R, Moran M, Gulmann C. If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS 2008; 116: 526-529.
22. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15: 415-420.
23. Renouf DJ, Wood-Baker R, Ionescu DN etal. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol 2009; 4: 486-491.
24. Au NH, Cheang M, Huntsman DG etal. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004; 204: 101-109.
25. Iwata T, Uramoto H, Sugio K etal. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer. Lung Cancer 2005; 50: 67-73.